Breaking News
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
March 21, 2018 - Premature babies have higher risks of health complications in Bangladesh
March 21, 2018 - Child’s temperament and parenting influence weight gain in babies
March 21, 2018 - Researchers find the heart to be capable of arrhythmia termination after local gene therapy
March 21, 2018 - Inhealthcare to provide digital infrastructure for NHS to help protect people from falls
March 21, 2018 - Flu Season Finally Slowing Down
March 21, 2018 - Mixed Results for Shorter DAPT in ACS Patients
March 21, 2018 - Scientists discover fish scale-derived collagen effective for healing wounds
March 21, 2018 - Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis
March 21, 2018 - Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients
March 21, 2018 - Researchers identify new treatment targets for lung diseases using big data
March 21, 2018 - Kids see more women in science than five decades ago
March 21, 2018 - Research shows link between chronic fatigue syndrome and lower thyroid hormone levels
March 21, 2018 - Alzheimer’s disease on the rise
March 21, 2018 - Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
March 21, 2018 - ‘Icebreaker’ protein opens genome for T cell development, researchers find
March 21, 2018 - Women in medicine shout #Metoo about sexual harassment at work
March 21, 2018 - Mother’s pre-pregnancy waist size may be linked to child’s autism risk
March 21, 2018 - Second hand marijuana smoke can cause serious damage
March 21, 2018 - International study shows benefits of using MRI at the start of prostate cancer diagnosis
March 20, 2018 - Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
March 20, 2018 - ECG Patch Ups At-Home Afib Diagnosis in mSToPS Trial
March 20, 2018 - ROS-scavenging nanozymes for anti-inflammation therapeutics
March 20, 2018 - Genomics England announces appointment of global genomics pioneer as first CEO
March 20, 2018 - Test flight at German Aerospace Center in Cologne demonstrates functionality of deficopter
March 20, 2018 - Music therapy helps treat combat-related psychological injuries in military personnel
March 20, 2018 - Innovative psychotherapeutic treatment protocol for obsessive-compulsive disorders
Prophylactic Tx Stems Bleeds in Hemophilia A with Inhibitors

Prophylactic Tx Stems Bleeds in Hemophilia A with Inhibitors

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Emicizumab (Hemlibra) prophylaxis prevented or significantly reduced bleeds, and was well tolerated, in pediatric patients with hemophilia A with factor VIII inhibitors.
  • In November 2017, the FDA approved emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with factor VIII inhibitors.

ATLANTA – Emicizumab (Hemlibra) prophylaxis prevented or significantly reduced bleeds, and was well tolerated, in pediatric patients with hemophilia A with factor VIII inhibitors, researchers reported here.

After a median of 38.1 weeks, 94.7% of 53 children in the study had zero treated bleeds, according to Guy Young, MD, of the Children’s Hospital of Los Angeles, and colleagues.

Overall, 41 bleeds, which were mostly minor bruising episodes that did not require treatment, were reported among 15 of 23 patients followed for at least 12 weeks, Young said at a press conference at the American Society of Hematology (ASH) meeting. Three of those bleeds required treatment, he added.

Young said the annualized bleeding rate was reduced 99%, to 0.2 bleeds per year for the entire population in the trial, compared with the rate of bleeds that occurred in the patients prior to treatment with emicizumab. The calculated annualized bleeding rate (ABR) before subcutaneous administration of emicizumab was as high as 30 bleeds per year among some of the children in the study.

“Emicizumab, a bispecific humanized monoclonal antibody administered subcutaneously, bridges FIXa and FX to restore the function of missing FVIIIa,” the authors explained.

In November 2017, the FDA approved emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with factor VIII inhibitors. Approval was based on data from HAVEN 1, an adult and adolescent trial, and HAVEN 2, a pediatric trial.

HAVEN 1 was a randomized, multicenter, open-label, phase III trial in 109 adult and adolescent males (ages 12-75 years; weight >40 kg) with hemophilia A with FVIII inhibitors who previously received either episodic (on-demand) or prophylactic treatment with bypassing agents.

Interim results of the HAVEN 2 trial presented at the 2017 International Society on Thrombosis and Haemostatis meeting. The results in 20 patients, ages 2-12 years, showed that subcutaneous, once-weekly emicizumab prophylaxis successfully prevented or reduced bleeds, provided clinically meaningful reductions in ABR versus prior bypassing agent (BPA) treatment, and was well tolerated.

The current findings are from 60 male children with a median age of 7 years. Three children ages >12 were enrolled because they weighed less than 40 kg. The vast majority (95%) of the children were diagnosed with severe hemophilia A, and they averaged six bleeds in the previous 24 weeks.

A total of 65 bleeds were reported in 20 patients, with eight occurring in a joint, two occurring in a muscle, and 55 classified as “other.” Of the latter, 40.0% were spontaneous, 55.4% were traumatic, and 4.6% were because of procedure/surgery, the authors explained.

Young told MedPage Today that all the patients kept bleeding diaries in which they recorded any kind of a bleed, including bruises that might have occurred in a fall. “They would record bleed, but they would also note that they didn’t treat that bleed. So the number of total bleeds will always exceed the number of treated bleeds,” he said.

When bleeds need treatment the patients generally use BPA to stop the bleeding, he said. “None of these bleeds became any sort of problem for the patients. Those bleeds were treated just the way they would if they were not on emicizumab, and they responded.”

Young noted that about 30% of patients who are treated with factor VIII for hemophilia developed neutralizing alloantibodies against the factor concentrate, and that can increase morbidity, as well as decrease health-related quality of life.

Patients with inhibitors have to undergo immune tolerance induction or use BPA. These treatments include the need for frequent intravenous dosing and often requiring emplacement of central lines which can lead to adverse events, such as infections and thrombosis.

Young said that in a proportion of these patients, immune tolerance fails to work, so that “any point in time in the United States, about 8% to 10% of people with hemophilia A have inhibitors. It is for these patients that we really need other treatments. They are often young people in their teens or early 20s. And these patients do not have other options.”

ASH press conference moderator Margaret Ragni, MD, of the University of Pittsburgh, said, “This is an exciting time in the management of these patients, not only in dealing with clotting issues but also in improvement of the quality of their life because of these advancements.”

“This study offers the potential to change the standard of care for both children with hemophilia A,” she noted. “In the study…95% of the patients experienced no bleeding events requiring treatment. This is outstanding and unusual. It suggests the drug is highly effective in preventing bleeding associated with hemophilia A.”

The trial was supported by Genentech/Roche.

Young disclosed relevant relationships with CSL Behring and Novo Nordisk.

Ragni disclosed relevant relationships with Alynlam, Bayer, Bioverativ, Biomarin, Genentech/Roche, MOGAM, Novo Nordisk, Sangamo, Shire and SPARK.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner


last updated

Tagged with:

About author

Related Articles